Voglibose dispersible tablet, capsule and method for preparing the same

A technology of voglibose and dispersible tablets, which is applied in the field of medicine, can solve the problems of affecting the therapeutic effect of drugs, long drug dissolution time, slow disintegration of ordinary tablets, etc., and achieves favorable dissolution and absorption, short onset time, The effect of convenience

Inactive Publication Date: 2008-07-16
JIANGSU WANBANG BIOPHARMLS +1
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the dosage form of voglibose on the market at home and abroad is ordinary tablets. The disintegration o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Voglibose dispersible tablet comprises the following components by weight percentage:

[0060] Voglibose 2g 0.16%

[0061] Lactose 1100g 88.1% diluent

[0062] Starch 100g 8.0% Disintegrant

[0063] Low-substituted hydroxypropyl cellulose 30g 2.4% disintegrant

[0064] Magnesium Stearate 10g 0.8% Lubricant

[0065] Povidone 6g 0.54% binder

[0066] The preparation method is as follows:

[0067] (1) Weigh voglibose and auxiliary materials according to the formula and pass through a 100-mesh sieve respectively, and set aside;

[0068] (2) In part of the disintegrant (accounting for 80% of the total amount) and the diluent, add the voglibose of the formula dosage, and mix well;

[0069] (3) Add binder and mix to make soft material, granulate with 18-24 mesh sieve, and dry the granules at 50-80°C;

[0070] (4) arrange with 20 mesh sieves after particle drying;

[0071] (5) Add the rest of the disintegrant (accounting for 20% of the total amount), and mix the lubrica...

Embodiment 2

[0074] Preparation method is identical with embodiment 1, just formula is different, comprises following component by weight percentage:

[0075] Voglibose 1g 0.06%

[0076] Microcrystalline Cellulose 500g 28.9% Disintegrant

[0077] Starch 1000g 57.7% Disintegrant

[0078] Low-substituted hydroxypropyl cellulose 200g 11.5% disintegrant

[0079] Magnesium Stearate 20g 1.2% Lubricant

[0080] Hypromellose 10g 0.64% Binder

Embodiment 3

[0082] Preparation method is identical with embodiment 1, just formula is different, comprises following component by weight percentage:

[0083] Voglibose 10g 1.35%

[0084] Sodium Carboxymethyl Starch 100g 13.5% Disintegrant

[0085] Mannitol 400g 54.05% Thinner

[0086] Low-substituted hydroxypropyl cellulose 100g 13.5% disintegrant

[0087] Micronized Silica Gel 100g 13.5% Lubricant

[0088] Talc 20g 2.7% lubricant

[0089] Gelatin paste 10g 1.4% binder

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a voglibose dispersible tablet and capsule and a preparation method thereof. The voglibose dispersible tablet comprises: 0.01-5 percent of voglibose, 1-99 percent of disintegrating agent, 0-98 percent of diluting agent; 0.5-20 percent of lubricant and fluidizer, 0.1-20 percent of bonding agent; wherein, the disintegrating agent is one or more selected from starch, modified starch, cellulose, microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, alginic acid and colloid magnesium aluminum silicate; the diluting agent is one or more selected from lactose, mannitol, sorbitol, sucrose, calcium sulfate, kaolin, dextrine and sodium chloride. The capsule preparation does not contain the bonding agent. The invention has the advantages that the voglibose dispersible tablet disintegrates swiftly and disperses evenly, the voglibose dispersible tablet can be disintegrated swiftly into fine particles and scattered evenly after being taken orally, which is beneficial for the dissolution and the absorption of the voglibose dispersible tablet with the short onset time. Disintegrated swiftly in three minutes; after being taken orally, the capsule shell quickly swells and splits, which conceals the discomfort caused by the capsule taken in mouth.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a voglibose dispersible tablet, a capsule and a preparation method thereof. Background technique [0002] Voglibose is a new generation of α-glucosidase inhibitors developed by Takeda Pharmaceutical Co., Ltd. in Japan. Improve the digestion and absorption of carbohydrates to improve postprandial hyperglycemia. It was first launched in Japan under the brand name Basen in 1994, and it is used for the treatment of postprandial blood sugar elevation in diabetes. In addition, this product is combined with pioglitazone to improve glucose tolerance. [0003] The α-glucosidase inhibitors currently on the market mainly include voglibose and acarbose. Compared with acarbose, voglibose has higher activity and lower dosage; Higher selectivity and lower intestinal side effects. The auspicious effect of voglibose is to delay the production and absorption of glucose, so the hypoglycemic ef...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/133A61K9/20A61K47/02A61K47/10A61K47/12A61K47/26A61K47/34A61K47/36A61K47/38A61K47/40A61K47/44A61P3/10
Inventor 林彬戴善彩王成
Owner JIANGSU WANBANG BIOPHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products